Codon 12 and 13 mutations in 170 colorectal cancer (CRC) and 66 gastric cancer (GC) specimens were analysed by an 'enriched' polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method. All identified mutations were verified by direct sequencing of the second PCR products. Among the 170 CRC specimens, mutations were identified in 47 (28%) and 13 (7.6%) cases in codons 12 and 13, respectively. In the 66 GC specimens examined, however, mutations in codons 12 and 13 were only detected in two (3.0%) and one (1.5%) cases, respectively. Mutations in both codon 12 and 13 were found in 3/170 (1.8%) CRCs and 1/66 (1.5%) GCs. Duplicate mutations were never identified in the same allele, which was confirmed by direct sequencing of the second amplified products. The majority of colorectal and gastric cancer cells with KRAS mutations are homogeneous because they have the same KRAS mutation. A few colorectal or gastric cancers, however, showed heterogeneity, as verified by the fact that single mutations were identified in the same allele.
Introduction
The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular response to growth signals. 1 KRAS is an oncogene located on chromosome 12p12.1 and is activated by point mutations at codons 12, 13, or 61. 2 The products of KRAS are guanosine triphosphate/ guanosine diphosphate (GTP/GDP) -binding proteins. These have a molecular weight of approximately 21 kDa and are found on the inner side of the cell membrane where they act as transmitters for cell proliferation and differentiation signals. 2 Activation of the KRAS gene by point mutations appears to play an important role in carcinogenesis by increasing the active GTP-bound form. This, in turn, increases the activity of transcription factors through binding to target proteins (Raf, phosphoinositide 3-kinase and Ral, guanine nucleotide dissociation stimulator). 3 -6 The KRAS mutation is common in various cancers; K Kimura, T Nagasaka, N Hoshizima et al. No duplicate KRAS mutation in the same allele in cancer cells mutations have been reported in 90% of human pancreatic cancers, 7 50% of lung adenocarcinomas, 8 40% of colorectal cancers (CRCs) 9 -11 and 8% of gastric cancers (GCs). 12 In CRCs, point mutations of KRAS occur early in the adenoma and are believed to contribute to tumour growth and the augmentation of atypia in adenoma. 11, 13, 14 Point mutation activates the KRAS gene if mutation occurs at the critical hot-spot coding sequences. Most (90%) KRAS mutations occur exclusively in codons 12 and 13, and less frequently in codon 61. 13, 15, 16 They have been detected by various methods, including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), single-strand conformation polymorphism, mutant allele-specific amplification and direct sequencing. 17 -21 'Enriched' PCR-RFLP is a highly sensitive detection method but only detects the codon 12 mutations. 22 It is possible, however, to detect the codon 13 mutation, as well as the codon 12 mutation, by inserting one artificial mismatched base pair in the forward primer of 'enriched' PCR-RFLP. 23 The present study aimed to use 'enriched' PCR-RFLP to investigate the nature of KRAS mutations at codons 12 and 13 in CRC and GC specimens.
Materials and methods

TISSUE SAMPLES
Tumour tissues and corresponding normal mucosa were obtained from 170 CRC and 66 GC patients who underwent curative surgery at Okayama University Medical Hospital and affiliated hospitals between 1994 and 1999. Normal mucosa was sampled from the surgical margin of the specimen before sampling of the tumour tissue to avoid contamination of the tumour cells. Tissues of non-necrotic areas of the tumour, as well as normal mucosa, were placed on ice immediately upon removal from the patient and subsequently frozen in liquid nitrogen. Tissues were stored at -80°C until DNA was extracted using digestion with proteinase K and phenol-chloroform extraction. Ethical approval for the study was obtained from the internal scientific and research ethics committee, and we obtained informed consent in writing from all patients.
'ENRICHED' PCR-RFLP ANALYSIS
First-step PCR amplification
DNA was amplified by a mutagenic PCR assay. To detect both KRAS codon 12 and 13 mutations, two mismatched nucleotide primers were introduced for synthesis of a 120 base-pair (bp) fragment with a MvaI restriction site to detect the codon 12 mutation and a BglI site to detect the codon 13 mutation ( Fig. 1A ). First-step PCR amplification was performed, with the forward primer (12 and 13 SP) being 5´-ACTGAATATAAACTTGTGGTAGTTGGCCCT-3´ and the reverse primer (wild AS) being 5´-AACAAGATTTACCTCTATTGTTGGATCA-3´. Oligonucleotides were purchased from Sigma-Aldrich, Tokyo, Japan. The underlined bases represent the introduced mismatches used to generate MvaI and BglI recognition sites for wild-type KRAS. The PCR was carried out in a final volume of 25 ml containing 10× PCR buffer, 1.5 mM MgCl 2 , 0.2 mM of each primer, 0.1 mM deoxynucleotidetriphosphate, 0.625 U of Taq polymerase (Ampli-TaqGold; Perkin-Elmer, Foster City, CA, USA) and approximately 50 ng of DNA. The conditions of amplification were as follows: 95°C for 11 min and 20 cycles of 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, and finally 5 min at 72°C.
Intermediate digestion
To detect the KRAS codon 12 mutations, 5 µl aliquots of the 120 bp fragment from the K Kimura, T Nagasaka, N Hoshizima et al.
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first-step PCR were digested with 10 U of the restriction enzyme MvaI (Takara, Kyoto, Japan) in a final volume of 20 µl and incubated at 37°C for 3 h (Fig. 1B) . This cleaved the wild-type fragments rendering them inaccessible for further amplification. To detect the KRAS codon 13 mutations, 5 µl aliquots of the 120 bp fragment from the first-step PCR reaction were digested with 8 U of the restriction enzyme BglI (Takara, Kyoto, Japan) in a final volume of 20 µl and incubated at 37°C for 3 h (Fig. 1E ).
Second-step PCR amplification for codon 12 mutation
Aliquots (1 µl) of the intermediate MvaI digests were used in the second-step PCR for the codon 12 mutation. The PCR was performed with the forward primer being 12 and 13 SP, and the reverse primer (12mt AS) being 5´-AACAAGATTTACCTCTATTCCTGGATCA-3´. The underlined bases represent the mismatches used to create the MvaI recognition site for internal control. The PCR was carried out in a final volume of 25 µl (Fig. 1C) .
Second-step PCR amplification for codon 13 mutation
Aliquots (1 µl) of the intermediate BglI digests were used in the second-step PCR for the codon 13 mutation. The PCR was performed with the forward primer being 12 and 13 SP, and the reverse primer (13mt AS) being 5´-AACAAGATTTGCCTCTATGGCTGGGATCA-3´. The underlined bases represent the mismatches used to create the BglI recognition site for internal control. The conditions of amplification were the same as for the second-step amplification for codon 12 (Fig. 1F ).
RFLP analysis of KRAS codon 12 and 13 mutations
Aliquots (25 µl) of each of the KRAS codon 12 and 13 products obtained after the secondstep PCR amplification were digested with the restriction enzymes MvaI for codon 12 and BglI for codon 13 at 37°C for 6 h in a final volume of 30 µl ( Figs 1D and 1G , respectively). The products were separated by electrophoresis on 3% agarose gel and then stained with ethidium bromide and photographed in UV light.
Analysis of the spectrum in KRAS mutations
The first and second-step amplification products of codons 12 and 13 were used to analyse for the presence of mutations in codons 12 and 13 of the KRAS gene. Sequencing was conducted according to the manufacturer's guidelines with sequencing primer: 5´-ACTGAATATAAACTTGTGGTA-3( Hitachi Autosequencer SQ-5500E, Hitachi Inc., Tokyo, Japan).
Results
The RFLP analysis of KRAS codons 12 and 13 is illustrated in Fig. 2 . This method of digestion with MvaI yields a 98 bp fragment if the sample contains a codon 12 mutation, but only yields a 69 bp band if the sample has only the normal (wild-type) cells ( Fig. 2A) . Digestion with BglI yields a 106 bp band; however, if the sample has a codon 13 mutant, only a 74 bp band can be identified if the sample consists of wild-type cells (Fig. 2B) .
The mutational spectrum of KRAS was accessed by direct sequencing of the first amplification products. As can be seen in Table 1 , KRAS mutations were identified in 57/170 (34%) CRC patients, and in 2/66 (3.0%) GC patients. The most common mutation in CRCs with the KRAS mutation was the G35A transitional mutation (24/57; 42%), and the G35T, G38A, G34A and G34T mutations were identified in 19%, 18%, 8.8% and 1.8% of cases, respectively. The G35C transversion mutation was identified in 3.5% cases. Interestingly, few samples showed multiple mutations in CRCs. Among them, 4/57 (7.0%) cases had codon 12 and/or 13 mutations (G35A, G35C; G35A, G38A; G34A, G35C, G37A; G34A, G37C). Of the two KRAS mutations in GC samples, one had a G35A transition mutation, and the other had both codon 12 and 13 mutations (G35A, G38A).
The mutation in the five cases with multiple mutations (four in CRC and one in GC) was investigated by direct sequencing of the second amplification products after digestion with either MvaI or BglI (Fig. 3) . Sequencing of the MvaI products, which can reveal multiple any-type mutations at codon 12, showed only single mutations, and no K Kimura, T Nagasaka, N Hoshizima et al. 
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Discussion
Tumour progression is an evolutionary process determined by two factors: generation of heterogeneity and the selection of the variants most suited to survival, growth and invasion. 24 In advanced stages of cancer, however, most of the tumour is entirely taken over by homogeneous malignant cells suited to survival. As far as can be deduced from the current examination of the KRAS mutation, the majority of advanced CRC or GC samples had a homogeneous mutational status.
The KRAS mutation in codons 12 and 13 was analysed by PCR-RFLP using a common primer set, but different restriction enzymes. The forward primer was improved by inserting 2 bp mismatches in codons 10 and 11 (GGA GCA to GGC CCA). This refinement introduced a BglI restriction site for codon 13 in the wild allele as well as an MvaI restriction site for codon 12. Reverse primers were also reformed to include internal control of the restriction enzyme MvaI or BglI. In this method, screening of both KRAS codon 12 and 13 mutations could be achieved by changing the restriction enzyme MvaI or BglI. 23 By using this method, we were able to demonstrate that the BRAF mutation as well as the KRAS mutation is also a significant oncogenic alteration leading to multiple promoter methylation along with CRC. 23 KRAS mutation was shown to be relatively common in CRC, but rare in GC. Only a small subset of tumours showed heterogeneity in KRAS mutations. Second amplification products were sequenced to reveal that tumours with both KRAS codon 12 and 13 mutations consisted of different clones, with only one mutation per clone. In this study, the KRAS codon 61 mutation was not examined; however, activated mutations in the RAS-RAF-MEK-ERK-MAP kinase pathway were shown to be coexisting in the cancer cells. Only a single codon 13 mutation and no concurrent codon 12 mutation was FIGURE 3: Direct sequencing result for the first polymerase chain reaction fragment from gastric cancer sample 01 showed both KRAS codon 12 (G35A) and 13 (G38A) mutations (A), but sequencing of the second amplification for codon 12 fragment showed only KRAS codon 12 (G35A) mutation (B). Sequencing of the second amplification for codon 13 product showed only KRAS codon 13 (G38A) mutation (C). Asterisks indicate the mismatch bases in the artificial forward primer observed clearly indicating that no single allele in the tumour had more than two types of mutational spectrum, either in the same codon or in different codons.
In conclusion, KRAS mutation is a common oncogenic alteration in CRC and is less common in GC. Single alteration may be enough to sustain the cancer cell and additional KRAS mutations in the same allele within a cell are never accumulated.
